Medication has become the first-line option for the management of lower urinary tract symptoms induced by benign prostatic hyperplasia (LUTS/BPH) for its advantages in controlling the symptoms, inhibiting BPH progression, and reducing serious complications and surgical risks.
Recent years have witnessed remarkable achievement in the studies of phosphodiesterase type 5 inhibitors (PDE5-Is) in the treatment of LUTS/BPH. PDE5-Is can effectively alleviate LUTS/BPH, with even better efficacy when combined with al-ARAs.
Written by:
He PB, Zha PJ, Xu DP. Are you the author?
Reference: Zhonghua Nan Ke Xue. 2014 Jul;20(7):651-6.
PubMed Abstract
PMID: 25095624
Article in Chinese.
